Figure 5: NANOG binds and upregulates the AurkA promoter.

(a) IHC of AURKA in oesophagus and liver sections of CTR and TG mice treated with high and low DOX for 48 h. Scale bars correspond to 50μm. The graphs to the right correspond to the percentage of AURKA-positive nuclear area for each condition in the basal (bas) and suprabasal (sb) epithelial layers of the oesophagus, or in the liver. CTR mice treated with low or high DOX were pooled (Hi+Lo). Values correspond to mean±s.e.m. of the indicated number of mice (n). Statistical significance was determined by the two-tailed Student’s t-test: *P<0.05; ***P<0.001. (b) Relative mRNA levels of the indicated genes in PB cells transfected with a mouse Nanog expressing vector or mock transfected (control). Samples were analysed 72 h after transfection. Values correspond to mean±s.e.m. (n=3 technical replicates). Statistical significance was determined by the two-tailed Student’s t-test: *P<0.05; ***P<0.001. (c) ChIP of NANOG in WT (+/+) or Nanog-KO (−/−) ESCs or in primary WT (+/+) or p53-KO (−/−) keratinocytes. The relative recovery with respect to NANOG ChIP in Nanog-KO ESCs is shown for Aurka promoter or intronic regions (see Supplementary Fig. 6a), or for the Oct4 promoter region. In the case of keratinocytes, data from two independent biological replicates each from a different newborn mouse are shown. Values correspond to mean±s.e.m. of qPCR triplicates (Aurka promoter or intronic regions) or duplicates (Oct4 promoter). Statistical significance versus NANOG ChIP in Nanog-KO (−/−) ESCs was determined by the two-tailed Student’s t-test: *P<0.05; **P<0.01; ***P<0.001.